Cargando…
Suppression of toxicity of the mutant huntingtin protein by its interacting compound, desonide
Identifying inhibitors of pathogenic proteins is the major strategy of targeted drug discoveries. This strategy meets challenges in targeting neurodegenerative disorders such as Huntington’s disease (HD), which is mainly caused by the mutant huntingtin protein (mHTT), an “undruggable” pathogenic pro...
Autores principales: | Song, Haikun, Wang, Cen, Zhu, Chenggang, Wang, Ziying, Yang, Huiya, Wu, Peng, Cui, Xiaotian, Botas, Juan, Dang, Yongjun, Ding, Yu, Fei, Yiyan, Lu, Boxun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
National Academy of Sciences
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8917382/ https://www.ncbi.nlm.nih.gov/pubmed/35238684 http://dx.doi.org/10.1073/pnas.2114303119 |
Ejemplares similares
-
A striatal-enriched intronic GPCR modulates huntingtin levels and toxicity
por: Yao, Yuwei, et al.
Publicado: (2015) -
Suppression of MAPK11 or HIPK3 reduces mutant Huntingtin levels in Huntington's disease models
por: Yu, Meng, et al.
Publicado: (2017) -
Discovery of an autophagy inducer J3 to lower mutant huntingtin and alleviate Huntington’s disease-related phenotype
por: Long, Jiahui, et al.
Publicado: (2022) -
Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin
por: Wang, Chuan-En, et al.
Publicado: (2008) -
Cdk5 phosphorylation of huntingtin reduces its cleavage by caspases: implications for mutant huntingtin toxicity
por: Luo, Shouqing, et al.
Publicado: (2005)